2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Breast Neoplasms
6
Carcinoma, Non-Small-Cell Lung
4
Recurrence
3
Pancreatic Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Uterine Cervical Neoplasms
1
Tracheal Diseases
1
Smoking Cessation
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Salivary Gland Neoplasms
1
Rhabdomyosarcoma
1
Peritoneal Neoplasms
1
Pain, Postoperative
1
Ovarian Neoplasms
1
Neurofibrosarcoma
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Mucopolysaccharidosis I
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphedema
1
Lung Neoplasms
1
Locally Advanced Rectal Cancer
1
Interventions
pembrolizumab
4
envafolimab
3
Nivolumab
3
Injections
2
trifluridine tipiracil drug combination
1
tebentafusp
1
surufatinib
1
sintilimab
1
linifanib
1
fludarabine
1
cobimetinib
1
TAK-981
1
Ipilimumab
1
Drug Therapy
1
Doxorubicin
1
Cyclophosphamide
1
Combined Modality Therapy
1
Bortezomib
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced or Metastatic Solid Tumors
×
Combined Modality Therapy
×
Clear all
NCT05957081
2025-12-30
MarkV-01
PharmAbcine
Phase 1
Recruiting
67 enrolled